Technology | Antiplatelet and Anticoagulation Therapies | July 14, 2016

BBMK Technologies Launches ClotMD Mobile App for Real-time Warfarin Management

Application sends real-time alerts on INR levels, scheduled testing and medication reminders to improve patient compliance

BBMK Technologies, ClotMD mobile app, real-time warfarin management

July 14, 2016 — BBMK Technologies recently announced the launch of ClotMD, a cloud-based application and mobile solution. The software-as-a-service (SaaS)-based solution allows healthcare providers to overcome the challenges of managing patients on anticoagulant medication, specifically warfarin.

Healthcare providers can easily manage on-site testing or home INR monitoring while enhancing patient medication adherence and improving their business. With ClotMD, providers have access to a fully integrated warfarin monitoring solution, allowing patients to engage actively in their health for an improved outcome on any computer or mobile device.

Patients who are on warfarin to manage anticoagulation require consistent and ongoing testing of INR levels to maintain within therapeutic range and avoid potentially serious health implications. ClotMD is designed to help healthcare providers manage their warfarin patient population while improving day-to-day business processes. Providers can now focus on patients who require their attention when they fall outside of target therapeutic range or are non-compliant with prescribed medication and/or testing.

The app works on any computer or mobile device, providing a real-time connection between providers and patients. ClotMD allows for convenient management of INR levels, dosing calculations and testing schedules.

The ClotMD mobile app makes patient-centric care possible by delivering real-time alerts on INR levels, scheduled testing and medication reminders.  Further, patients can also receive automatic notifications from their healthcare provider alerting them to a warfarin dosage change. A built-in diet library offers another layer of support for patients who want to be proactive regarding their health. History of current and previous INR levels can be tracked and shared by the patient.

For more information: www.clotmd.com

Related Content

Tailor PCI trial showed genetic testing may play a role in personalizing antiplatelet therapy after PCI.
News | Antiplatelet and Anticoagulation Therapies | September 02, 2020
September 2, 2020 — An international, first-of-its-kind cardiology trial used personalized genetic testing to reduce
Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. #ACC20 #ACC2020

Naveen Pereira, M.D., co-principal investigator of the TAILOR-PCI study, explaining the conclusions of the late-breaking trial data during the virtual ACC20 meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 28, 2020
March 28, 2020 — The TAILOR-PCI trial that used genetic testing to guide which antiplatelet medication was given to p
The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...